166 related articles for article (PubMed ID: 20384566)
1. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries.
Godman B; Bucsics A; Burkhardt T; Schmitzer M; Wettermark B; Wieninger P
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):199-207. PubMed ID: 20384566
[TBL] [Abstract][Full Text] [Related]
2. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.
Godman B; Burkhardt T; Bucsics A; Wettermark B; Wieninger P
Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):475-84. PubMed ID: 19817531
[TBL] [Abstract][Full Text] [Related]
3. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future.
Vončina L; Strizrep T; Godman B; Bennie M; Bishop I; Campbell S; Vlahović-Palčevski V; Gustafsson LL
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):469-79. PubMed ID: 21831028
[TBL] [Abstract][Full Text] [Related]
4. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?
Kalaba M; Godman B; Vuksanović A; Bennie M; Malmström RE
J Comp Eff Res; 2012 Nov; 1(6):539-49. PubMed ID: 24236473
[TBL] [Abstract][Full Text] [Related]
5. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction.
Coma A; Zara C; Godman B; Agustí A; Diogène E; Wettermark B; Haycox A
Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):569-81. PubMed ID: 19941434
[TBL] [Abstract][Full Text] [Related]
6. Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries.
Bucsics A; Godman B; Burkhardt T; Schmitzer M; Malmström RE
Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):809-19. PubMed ID: 23252361
[TBL] [Abstract][Full Text] [Related]
7. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions.
Markovic-Pekovic V; Skrbić R; Godman B; Gustafsson LL
Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):661-71. PubMed ID: 23186404
[TBL] [Abstract][Full Text] [Related]
8. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications.
Godman B; Shrank W; Andersen M; Berg C; Bishop I; Burkhardt T; Garuoliene K; Herholz H; Joppi R; Kalaba M; Laius O; McGinn D; Samaluk V; Sermet C; Schwabe U; Teixeira I; Tilson L; Tulunay FC; Vlahović-Palčevski V; Wendykowska K; Wettermark B; Zara C; Gustafsson LL
Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):707-22. PubMed ID: 21155704
[TBL] [Abstract][Full Text] [Related]
9. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.
Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmström RE
Int J Clin Pract; 2013 Sep; 67(9):853-62. PubMed ID: 23560825
[TBL] [Abstract][Full Text] [Related]
10. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs.
Godman B; Sakshaug S; Berg C; Wettermark B; Haycox A
Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):121-9. PubMed ID: 21351864
[TBL] [Abstract][Full Text] [Related]
11. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.
Hesse U; Godman B; Petzold M; Martin A; Malmström RE
Appl Health Econ Health Policy; 2013 Dec; 11(6):677-85. PubMed ID: 24105097
[TBL] [Abstract][Full Text] [Related]
12. Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi.
Abuelkhair M; Abdu S; Godman B; Fahmy S; Malmström RE; Gustafsson LL
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):115-24. PubMed ID: 22280201
[TBL] [Abstract][Full Text] [Related]
13. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.
Fraeyman J; Van Hal G; Godman B; Beutels P
Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):141-51. PubMed ID: 23402454
[TBL] [Abstract][Full Text] [Related]
14. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland.
Bennie M; Godman B; Bishop I; Campbell S
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):125-30. PubMed ID: 22280202
[TBL] [Abstract][Full Text] [Related]
15. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?
Bennie M; Bishop I; Godman B; Campbell S; Miranda J; Finlayson AE; Gustafsson LL
Qual Prim Care; 2013; 21(1):7-15. PubMed ID: 23735629
[TBL] [Abstract][Full Text] [Related]
16. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications.
Woerkom Mv; Piepenbrink H; Godman B; Metz Jd; Campbell S; Bennie M; Eimers M; Gustafsson LL
J Comp Eff Res; 2012 Nov; 1(6):527-38. PubMed ID: 24236472
[TBL] [Abstract][Full Text] [Related]
17. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
Altagracia-Martínez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI
Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
[TBL] [Abstract][Full Text] [Related]
18. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications.
McGinn D; Godman B; Lonsdale J; Way R; Wettermark B; Haycox A
Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):73-85. PubMed ID: 20121565
[TBL] [Abstract][Full Text] [Related]
19. European countries with small populations can obtain low prices for drugs: Lithuania as a case history.
Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A
Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703
[TBL] [Abstract][Full Text] [Related]
20. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
